Prometheus Biosciences, Inc. Quarterly Additional Paid in Capital in USD from Q4 2020 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
Prometheus Biosciences, Inc. quarterly Additional Paid in Capital history and growth rate from Q4 2020 to Q1 2023.
  • Prometheus Biosciences, Inc. Additional Paid in Capital for the quarter ending March 31, 2023 was $1.07B, a 150% increase year-over-year.
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2023 $1.07B +$642M +150% Mar 31, 2023 10-Q 2023-05-09
Q4 2022 $1.01B +$583M +137% Dec 31, 2022 10-Q 2023-05-09
Q3 2022 $525M +$104M +24.6% Sep 30, 2022 10-Q 2022-11-09
Q2 2022 $447M +$32.7M +7.88% Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $428M +$14.8M +3.59% Mar 31, 2022 10-Q 2022-05-12
Q4 2021 $424M +$423M +26348% Dec 31, 2021 10-K 2023-02-28
Q3 2021 $422M Sep 30, 2021 10-Q 2021-11-12
Q2 2021 $415M Jun 30, 2021 10-Q 2021-08-11
Q1 2021 $413M Mar 31, 2021 10-Q 2021-05-13
Q4 2020 $1.61M Dec 31, 2020 10-K 2022-03-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.